New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023

By /

Transgene and NEC Corporation announced that new data will be presented on TG4050, an individualized neoantigen cancer vaccine, at the American Association for Cancer Research Annual Meeting in Orlando, Florida.

Scroll to Top